Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.

被引：0
|
作者：
Rea, Delphine
Mauro, Michael J.
Hochhaus, Andreas
Boquimpani, Carla
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna G.
Kim, Dong-Wook
Apperley, Jane
Cortes, Jorge E.
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sara
Bedoucha, Veronique
Minami, Yosuke
机构：
[1] Hop St Louis, Paris, France
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[4] HEMORIO, State Inst Hematol Arthur Siquiera Cavalcanti, Rio De Janeiro, Brazil
[5] Almazov Natl Med Res Ctr, Minist Hlth, St Petersburg, Russia
[6] Russian Res Inst Hematol & Transfusiol, St Petersburg, Russia
[7] Natl Res Ctr Hematol, Moscow, Russia
[8] Uijeongbu Eulji Med Ctr, Uijeongbu Si, South Korea
[9] Imperial Coll London, Ctr Haematol, London, England
[10] Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Novartis Pharma AG, Basel, Switzerland
[14] Kobe Univ Hosp, Dept Transfus Med & Cell Therapy, Kobe, Hyogo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7004
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
    Rea, Delphine
    Hochhaus, Andreas
    Mauro, Michael J.
    Minami, Yosuke
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna
    Kim, Wook
    Apperley, Jane F.
    Cortes, Jorge E.
    Abdo, Andre
    Fogliatto, Laura Marie
    Kim, Dennis Dong Hwan
    le Coutre, Philipp
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem
    Chee, Lynette
    Garcia-Gutierrez, Valentin
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Boquimpani, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
  • [2] 96-Week Update from the Phase 3 ASCEMBL Study for Evaluating the Safety and Efficacy of Asciminib versus Bosutinib in Patients with chronic phase chronic myeloid Leukemia after Pretreatment with 2 TKIs
    Hochhaus, A.
    Rea, D.
    Saussele, S.
    Buske, S.
    Balabanov, S.
    Lang, F.
    Sauer, T.
    Gattermann, N.
    Mauro, M.
    Minami, Y.
    Lomaia, E.
    Voloshin, S.
    Turkina, A.
    Kim, D. -W
    Apperley, J.
    Cortes, J.
    Abdo, A.
    Fogliatto, L. M.
    Kim, D.
    Annunziata, M.
    Hughes, T.
    Chaudhri, N.
    Chee, L.
    Garcia-Gutierrez, V
    Sasaki, K.
    Kapoor, S.
    Allepuz, A.
    Quenet, S.
    Bedoucha, V
    Boquimpani, C.
    le Coutre, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 17 - 17
  • [3] Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Mauro, Michael
    Cortes, Jorge E.
    Apperley, Jane F.
    Gutierrez, Valentin Garcia
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Zhang, Yifan
    Hochhaus, Andreas
    BLOOD, 2022, 140 : 6757 - 6759
  • [4] Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
    Hochhaus, Andreas
    Boquimpani, Carla
    Rea, Delphine
    Minami, Yosuke
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna G.
    Kim, Dong-Wook
    Apperley, Jane
    Cortes, Jorge E.
    Abdo, Andre
    Fogliatto, Laura Maria
    Kim, Dennis Dong Hwan
    Le Coutre, Philipp D.
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem A.
    Chee, Lynette C. Y.
    Gutierrez, Valentin Garcia
    Sasaki, Koji
    Aimone, Paola
    Allepuz, Alex
    Quenet, Sarah
    Bedoucha, Veronique
    Mauro, Michael J.
    BLOOD, 2020, 136
  • [5] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
    Mauro, Michael
    Hochhaus, Andreas
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Apperley, Jane
    Garcia-Gutierrez, Valentin
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
  • [6] Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Followup from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population
    Mauro, Michael
    Minami, Yosuke
    Hochhaus, Andreas
    Lomaia, Elza
    Voloshin, Sergei
    Turkina, Anna
    Kim, Dong-Wook
    Apperley, Jane F.
    Cortes, Jorge
    Abdo, Andre N. R.
    Fogliatto, Laura Maria
    Kim, Dennis Dong Hwan
    le Coutre, Philipp
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem A.
    Chee, Lynette C. Y.
    Gutierrez, Valentin Garcia
    Sasaki, Koji
    Freitas, Carla Maria Boquimpani De Moura
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Rea, Delphine
    BLOOD, 2023, 142
  • [7] A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Minami, Yosuke
    Allepuz, Alex
    Polydoros, Fotis
    Bedoucha, Veronique
    Aimone, Paola
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
    Smith, B. Douglas
    Cortes, Jorge E.
    Rea, Delphine
    Mauro, Michael J.
    Patwardhan, Pallavi
    Maegawa, Rodrigo
    Zacker, Christopher
    Corbin, Regina
    Keeping, Sam
    Sasaki, Koji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S334
  • [9] Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First -in -Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
    Mauro, Michael J.
    Minami, Yosuke
    Rea, Delphine
    Hochhaus, Andreas
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna G.
    Kim, Dong-Wook
    Apperley, Jane F.
    Cortes, Jorge E.
    Abdo, Andre N. R.
    Fogliatto, Laura
    Kim, Dennis Dong Hwan
    le Coutre, Philipp D.
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem A.
    Chee, Lynette C. Y.
    Garcia Gutierrez, Valentin
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Bedoucha, Veronique
    Boquimpani, Carla
    BLOOD, 2021, 138
  • [10] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
    Dahlen, Torsten
    Kockerols, Camille C. B.
    Ferreira, Germano
    Westerweel, Peter E.
    Mayer, Jiri
    Allepuz, Alex
    Wormser, David
    Yau, Lillian
    Zackova, Daniela
    BLOOD, 2022, 140 : 3889 - 3890
12345